Current Clinical Trials

List of Current Clinical Research Trials at the Shiley Eye Institute

An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTE-ROP-1920 Study8058085 Nudleman, Eric
A Multi-center, Double-Masked, Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered with a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The Chaperone Study)805073 Robbins, Shira
A Multi-center, Double-Masked, Randomized, Vehicle-Controlled 12-Month (with a 12-month, Double-Masked Extension) Parallel Comparison of the Safety and Efficacy of 0.1% and 0.2% CBT-001 versus Vehicle, Dosed Twice-Daily, in Patients with Pterygium804723 Haw, Weldon
Natural history of Retinal Degeneration804279 Borooah, Shyamanga
Improving Corneal Ulcer Outcomes with Unbiased Pathogen and Antimicrobial Resistance Detection [Protocol Title: capriCORN – Cataloging and Analysis of Pathogens, Resistomes, and Inflammatory-markers in the CORNea]804035 McClean, Esmeralda
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene802624 Borooah, Shyamanga
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of Xlinked Retinitis Pigmentosa Associated with Variants in the RPGR gene802611 Borooah, Shyamanga
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)802493 Kikkawa, Don
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene with Early to Moderate Vision Loss801888 Borooah, Shyamanga
Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes801770 McClean, Esmeralda
A Phase 1/2A Study to Assess the Safety and Efficacy of OCU400 for NR2E3-Related Retinitis Pigmentosa801761 Borooah, Shyamanga
Phase 3 Randomized, Controlled Study of AAV2/5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene801491 Borooah, Shyamanga
A Phase 3, Randomized, Open-Label, Multi-Center Study of a Recombinant Adeno-Associated Viral Vector (AAV5-OPTIRPE65) for Gene Therapy in Adults and Children with Confirmed Biallelic RPE65 Mutation-Associated Retinal Dystrophy800728 Borooah, Shyamanga
Vista: A Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control210119 Borooah, Shyamanga
A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients with Chronic (Inactive) Thyroid Eye Disease201707 Liu, Catherine Yunxiang
AGN-151587 Single Ascending Dose Study in Participants with LCA10-IVS26191760 Borooah, Shyamanga

If you would like more information on any particular trial, please email shileyclinicaltrials@health.ucsd.edu or visit our contact page.